Long-term valve durability, stroke complications, and costs remain important considerations when treating patients with transcatheter aortic valve replacement (TAVR) for aortic stenosis. Currently, Medicare reimbursement in the United States is limited to transfemoral TAVR based on cost-effectiveness data. Also, the risk of stroke persists, with the STS/ACC TVT Registry reporting a 30-day stroke rate of 2.8% in general practice. In this live webcast, four internationally renowned experts will discuss important trial data presented at TCT 2014, which will further illuminate the challenges of stroke, cost, and durability associated with TAVR.
Click Here to access this CME Program
January 21st, 2015
July 21st, 2015